Low- and high-density lipoprotein cholesterol goal attainment in dyslipidemic women: The Lipid Treatment Assessment Project (L-TAP) 2

Santos, Raul D.; Waters, David D.; Tarasenko, Lisa; Messig, Michael; Jukema, J. Wouter; Ferrières, Jean; Verdejo, Juan; Chiang, Cheng Wen

doi:10.1016/j.ahj.2009.08.009

Cited by 40 publications

(29 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the proportions of patients who attained their LDL-C goal were greater in women than in men overall (51.9% vs. 47.4%), the multivariate adjusted analysis revealed that women were less likely than men to attain their goal. The reason for this difference is unclear, but a similar finding has been reported in several studies [35][36][37][38][39] . For example, in the NCEP Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II, the adjusted OR for LDL-C goal attainment was 0.76 (95% CI: 0.62 -0.93) for women compared with men with CHD or CHD risk equivalents 35) .…”

supporting

confidence: 50%

See 1 more Smart Citation

Suboptimal Control of Lipid Levels: Results from 29 Countries Participating in the Centralized Pan-Regional Surveys on the Undertreatment of Hypercholesterolaemia (CEPHEUS)

Chiang

Ferrières

Gotcheva

et al. 2016

J Atheroscler Thromb

Self Cite

View full text Add to dashboard Cite

. Epidemiological studies have shown that elevated serum lipid and low-density lipoprotein 568 CEPHEUS studies were conducted in 29 countries across Asia (Hong Kong, Indonesia, Malaysia, Philippines, South Korea, Taiwan, Thailand, and Vietnam) 23,26) , Western Europe (Belgium, Finland, France, Greece, Ireland, Luxembourg, Netherlands, and Turkey) 22,27,28) , Eastern Europe (Bulgaria, Poland, and Russia) 20) , the Middle East (United Arab Emirates, Bahrain, Jordan, Kuwait, Oman, Qatar, and Saudi Arabia) 21,25) , and Africa (Algeria, Egypt. and South Africa) 24) . In each country, the study protocol was reviewed and approved by the Institutional Review Board and Ethics Committee governing each participating center. The surveys were performed in accordance with the Declaration of Helsinki and the International Conference on Harmonisation guidelines for Good Clinical Practice 29) , and all participating patients provided written informed consent before enrolment.Each survey was a single-visit study and recruitment was carried out in two stages. In the first stage, physicians with experience of treating dyslipidaemia were invited to participate. Physicians who agreed to participate were asked to complete a questionnaire about their general attitude toward the diagnosis of hypercholesterolaemia, their perception of existing guidelines, and their knowledge about available treatment options (Supplemental Fig. 1). In the second stage, eligible patients who attended a regular scheduled physician visit were consecutively invited to participate in the study. Patients were eligible to participate if they were ≥ 18 years and had been receiving LLDs for at least 3 months without dose changes for at least 6 weeks. Patients were excluded if they were found to have participated in any interventional clinical study in the preceding 90 days, were unable or unwilling to provide informed consent, or were personally involved in the conduct of the surveys. In all countries except France, before being assessed by the physician, patients also completed a questionnaire, the aim of which was to assess their personal perception of hypercholesterolaemia, their current LLD regimen, their adherence to this regimen, and their satisfaction with the treatment (Supplemental Fig. 2).For each individual, physicians also completed a patient record form, which included information on the patient's demographics, current LLD therapy, and reason for initiating LLD therapy. Physicians also recorded the presence of known CV risk factors, such as smoking, diabetes mellitus, family history of premature coronary heart disease (CHD; defined as having a first-degree relative with clinical CHD or sudden death before the age of 55 years for men or 65 years for women), hypertension (defined as blood pressure cholesterol (LDL-C) levels, in particular, are strongly associated with an increased risk of incident CV disease in many populations worldwide 3, 4) . Most guidelines include the reduction of LDL-C levels as a primary therapeutic target for the reduction o...

show abstract

supporting

confidence: 50%

“…A similar sex disparity was observed in a Chinese study, with an adjusted OR of 0.77 (95% CI: 0.60 -0.90) for women relative to men in patients at high or very high CV risk 36) . Although differences in treatment between men and women have been suggested to explain this disparity [37][38][39] …”

mentioning

confidence: 99%

Suboptimal Control of Lipid Levels: Results from 29 Countries Participating in the Centralized Pan-Regional Surveys on the Undertreatment of Hypercholesterolaemia (CEPHEUS)

Chiang

Ferrières

Gotcheva

et al. 2016

J Atheroscler Thromb

Self Cite

View full text Add to dashboard Cite

show abstract

“…Shammas et al 37 analyzed gender differences in lipid management in 4324 patients enrolled in a community lipid clinic and found that fewer women were at LDL-C goal than men (64% vs. 71.6%) by the last visit. Santos et al 38 found that women in the high-risk/coronary heart disease group were less likely to attain LDL-C goal than men (62.6% vs. 70.6%; P , .0001). These results suggest that women may be treated less aggressively than men.…”

Section: Discussionmentioning

confidence: 96%

A secondary prevention lipid clinic reaches low-density lipoprotein cholesterol goals more often than usual cardiology care with coronary heart disease

Birtcher

Greisinger

Brehm

et al. 2010

Journal of Clinical Lipidology

View full text Add to dashboard Cite

“…12 Studies in Europe and the US found that the LDL control rate ranged from 30% to 55%. [13][14][15][16][17] Similarly, a study of dyslipidaemia management in South Asia including China, South Korea, Malaysia, and Singapore revealed that only 48% of patients attained pre-defined low-density lipoprotein-cholesterol goals. 18 Similar to other chronic conditions, the reasons for poor (lipid) control are multifactorial and may include patient, physician, and health care delivery factors.…”

Section: Resultsmentioning

confidence: 99%

Therapeutic inertia in the management of hyperlipidaemia in type 2 diabetic patients: a cross-sectional study in the primary care setting

Man¹,

Chen²,

Lau³

et al. 2016

Hong Kong Med J

View full text Add to dashboard Cite

Objectives:To study the prevalence of therapeutic inertia in lipid management among type 2 diabetic patients in the primary care setting and to explore associated factors.Methods: This was a cross-sectional study involving type 2 diabetic patients with suboptimal lipid control followed up in all general out-patient clinics of Kowloon Central Cluster in Hong Kong from 1 October 2011 to 30 September 2013. Main outcome measures included prevalence of therapeutic inertia in low-density lipoprotein management among type 2 diabetic patients and its association with patient and physician characteristics.Results: Based on an agreed standard, lipid control was suboptimal in 49.1% (n=9647) of type 2 diabetic patients who attended for a regular annual check-up (n=19 662). Among the sampled 369 type 2 diabetic patients with suboptimal lipid control, therapeutic inertia was found to be present in 244 cases, with a prevalence rate of 66.1%. When the attending doctors' profiles were compared, the mean duration of clinical practice was significantly longer in the therapeutic inertia group than the non-therapeutic inertia group. Doctors without prior training in family medicine were also found to have a higher rate of therapeutic inertia. Patients in the therapeutic inertia group had Therapeutic inertia in the management of hyperlipidaemia in type 2 diabetic patients: a cross-sectional study in the primary care setting

show abstract

Low- and high-density lipoprotein cholesterol goal attainment in dyslipidemic women: The Lipid Treatment Assessment Project (L-TAP) 2

Cited by 40 publications

References 28 publications

Suboptimal Control of Lipid Levels: Results from 29 Countries Participating in the Centralized Pan-Regional Surveys on the Undertreatment of Hypercholesterolaemia (CEPHEUS)

Suboptimal Control of Lipid Levels: Results from 29 Countries Participating in the Centralized Pan-Regional Surveys on the Undertreatment of Hypercholesterolaemia (CEPHEUS)

A secondary prevention lipid clinic reaches low-density lipoprotein cholesterol goals more often than usual cardiology care with coronary heart disease

Therapeutic inertia in the management of hyperlipidaemia in type 2 diabetic patients: a cross-sectional study in the primary care setting

Contact Info

Product

Resources

About